Cargando…
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
BACKGROUND: REGOBONE multicohort study explored the efficacy and safety of regorafenib for patients with advanced bone sarcomas; this report details the cohort of patients with relapsed advanced or metastatic chordoma. METHODS: Patients with relapsed chordoma progressing despite 0-2 prior lines of s...
Autores principales: | Le Cesne, A., Chevreau, C., Perrin, C., Italiano, A., Hervieu, A., Blay, J.Y., Piperno-Neumann, S., Saada-Bouzid, E., Bertucci, F., Firmin, N., Kalbacher, E., Narciso, B., Schiffler, C., Yara, S., Jimenez, M., Bouvier, C., Vidal, V., Chabaud, S., Duffaud, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265601/ https://www.ncbi.nlm.nih.gov/pubmed/37285716 http://dx.doi.org/10.1016/j.esmoop.2023.101569 |
Ejemplares similares
-
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
por: Moreau-Bachelard, C., et al.
Publicado: (2022) -
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015) -
REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017) -
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
por: Pautier, P., et al.
Publicado: (2021) -
Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study
por: Bompas, Emmanuelle, et al.
Publicado: (2018)